HC Wainwright Reiterates Buy Rating for VolitionRX Ltd (VNRX)

VolitionRX Ltd (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday. They presently have a $10.00 price objective on the medical research company’s stock. HC Wainwright’s price objective would indicate a potential upside of 177.78% from the company’s current price.

VolitionRX (NYSEAMERICAN:VNRX) opened at $3.60 on Monday. VolitionRX has a twelve month low of $2.08 and a twelve month high of $5.45.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates Buy Rating for VolitionRX Ltd (VNRX)” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2017/11/15/hc-wainwright-reiterates-buy-rating-for-volitionrx-ltd-vnrx.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lagoda Investment Management L.P. lifted its holdings in VolitionRX by 7.4% in the second quarter. Lagoda Investment Management L.P. now owns 3,155,692 shares of the medical research company’s stock valued at $11,171,000 after acquiring an additional 216,613 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in VolitionRX by 177.1% in the second quarter. Bank of New York Mellon Corp now owns 30,376 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 19,414 shares during the last quarter. Finally, Leisure Capital Management acquired a new position in VolitionRX in the third quarter valued at approximately $193,000.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply